NewAmsterdam’s obicetrapib holds potential to become first CETP inhibitor to advance to clinical… EP News Bureau Jul 25, 2024 According to GlobalData, NewAmsterdam’s obicetrapib is expected to be the most promising agent to launch in the dyslipidemia…
Lupin gets US FDA approval for Colesevelam Hydrochloride Tablets EP News Bureau Dec 18, 2020 They are indicated for reducing elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia
